ZAI LAB LIMITED Outstanding Bonds
Note series still outstanding, nearest maturity first. Terms are from each offering's final pricing term sheet on SEC EDGAR; a reopening of the same CUSIP adds to its principal. Interest per payment = principal × coupon ÷ payments per year. Outstanding = principal issued minus each filed exchange, tender, redemption or conversion; it is (m) where the retired amount was not filed. Interest per payment uses the outstanding principal.
| Notes | Principal issued | Outstanding | Coupon | Trade date | Issue / settlement date | Maturity date | Interest payment dates | Interest per payment | Annual coupon interest | Optional redemption | Retired | Priced |
|---|
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |